Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 25;2013(9):CD009278.
doi: 10.1002/14651858.CD009278.pub2.

Combined oestrogen and progesterone for preventing miscarriage

Chi Eung Danforn Lim  1 , Karen K W Ho, Nga Chong Lisa Cheng, Felix W S Wong
Affiliations

Combined oestrogen and progesterone for preventing miscarriage

Chi Eung Danforn Lim et al. Cochrane Database Syst Rev. .

Abstract

Background: Historically, oestrogen and progesterone were each commonly used to save threatened pregnancies. In the 1940s it was postulated that their combined use would be synergistic and thereby led to the rationale of combined therapy for women who risked miscarriage.

Objectives: To determine the efficacy and safety of combined oestrogen and progesterone therapy to prevent miscarriage.

Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (23 June 2013) CENTRAL (OVID) (The Cochrane Library 2013, Issue 6 of 12), MEDLINE (OVID) (1946 to June Week 2 2013), OLDMEDLINE (1946 to 1965), Embase (1974 to Week 25 2013), Embase Classic (1947 to 1973), CINAHL (1994 to 23 June 2013) and reference lists of retrieved studies.

Selection criteria: We included randomised controlled trials that assessed the effectiveness of combined oestrogen and progesterone for preventing miscarriage. We included one stratified randomised trial and one quasi-randomised trials. Cluster-randomised trials were eligible for inclusion but none were identified. We excluded studies published only as abstracts.We included studies that compared oestrogen and progesterone versus placebo or no intervention.

Data collection and analysis: Two review authors independently assessed trials for inclusion and assessed trial quality. Two review authors extracted data. Data were checked for accuracy.

Main results: Two trials (281 pregnancies and 282 fetuses) met our inclusion criteria. However, the two trials had significant clinical and methodological heterogeneity such that a meta-analysis combining trial data was considered inappropriate.One trial (involving 161 pregnancies) was based on women with a history of diabetes. It showed no statistically significant difference between using combined oestrogen and progestogen and using placebo for all our proposed primary outcomes, namely, miscarriage (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.32 to 2.80), perinatal death (RR 0.94, 95% CI 0.53 to 1.69) and preterm birth (less than 34 weeks of gestation) (RR 0.91, 95% CI 0.80 to 1.04). In terms of this review's secondary outcomes, use of combined oestrogen and progestogen was associated with an increased risk of maternal cancer in the reproductive system (RR 6.65, 95% CI 1.56 to 28.29). However, for the outcome of cancer other than that of the reproductive system in mothers, there was no difference between groups. Similarly, there were no differences between the combined oestrogen and progestogen group versus placebo for other secondary outcomes reported: low birthweight of less than 2500 g, genital abnormalities in the offspring, abnormalities other than genital tract in the offspring, cancer in the reproductive system in the offspring, or cancer other than of the reproductive system in the offspring.The second study was based on pregnant women who had undergone in-vitro fertilisation (IVF). This study showed no difference in the rate of miscarriage between the combined oestrogen and progesterone group and the no treatment group (RR 0.66, 95% CI 0.23 to 1.85). The study did not report on this review's other primary outcomes (perinatal death or rates of preterm birth), nor on any of our proposed secondary outcomes.

Authors' conclusions: There is an insufficient evidence from randomised controlled trials to assess the use of combined oestrogen and progesterone for preventing miscarriages. We strongly recommend further research in this area.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 1 Miscarriage.
1.2
1.2. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 2 Perinatal death.
1.3
1.3. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 3 Preterm birth (less than 34 weeks of gestation).
1.4
1.4. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 4 Low birthweight of less than 2500 g.
1.5
1.5. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 5 Genital abnormalities in offspring.
1.6
1.6. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 6 Abnormalities other than of the genital tract in offspring.
1.7
1.7. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 7 Cancer in the reproductive system in offspring.
1.8
1.8. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 8 Cancer other than of the reproductive system in offspring.
1.9
1.9. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 9 Cancer in the reproductive system in mothers.
1.10
1.10. Analysis
Comparison 1 Combined oestrogen and progestogen (other than progesterone) versus placebo, Outcome 10 Cancer other than of the reproductive system in mothers.
2.1
2.1. Analysis
Comparison 2 Combined oestrogen and progesterone versus no hormonal treatment, Outcome 1 Miscarriage.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

MRC 1955 {published data only}
    1. Beral V, Colwell L. Randomised trial of high doses of stilboestrol and ethisterone in pregnancy: long‐term follow‐up of mothers. British Medical Journal 1980;281:1098‐101. - PMC - PubMed
    1. Beral V, Colwell L. Randomised trial of high doses of stilboestrol and ethisterone therapy in pregnancy: long‐term follow‐up of the children. Journal of Epidemiology & Community Health 1981;35:155‐60. - PMC - PubMed
    1. Medical Research Council. The use of hormones in the management of pregnancy in diabetics. Lancet 1955;2:833‐6. - PubMed
Prietl 1992 {published data only}
    1. Prietl G, Diedrich K, Ven HH, Luckhaus J, Krebs D. The effect of 17alpha‐hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial. Human Reproduction 1992;7(1):1‐5. - PubMed

References to studies excluded from this review

Berle 1977 {published data only}
    1. Berle P, Behnke K. The treatment of threatened abortion [Uber Behandlungserfolge der drohenden Fehlgeburt]. Geburtshilfe und Frauenheilkunde 1977;37(2):139‐42. - PubMed
Crowder 1950 {published data only}
    1. Crowder RE, Bills ES, Broadbent JS. The management of threatened abortion: a study of 100 cases. American Journal of Obstetrics and Gynecology 1950;60(4):896‐9. - PubMed
Lightman 1999 {published data only}
    1. Lightman A, Kol S, Itskovitz‐Eldor J. A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles. Human Reproduction 1999;14(10):2596‐9. - PubMed
Sathanandan 1991 {published data only}
    1. Sathanandan M, Macnamee MC, Rainsbury P, Wick K, Brinsden P, Edwards RG. Replacement of frozen‐thawed embryos in artificial and natural cycles: a prospective semi‐randomized study. Human Reproduction 1991;6(5):685‐7. - PubMed

Additional references

Abu‐Musa 1998
    1. Abu‐Musa A, Hannoun A, Khalil A, Masaad Z, Karam K. Artificial preparation for oocyte donation using synthetic estrogen and progestogen. Clinical and Experimental Obstetrics and Gynecology 1998;25(3):83‐5. - PubMed
Balasch 1987
    1. Balasch J. Luteal phase insufficiency: clinical aspects. Journal of Steroid Biochemistry 1987;27(1‐3):393‐7. - PubMed
Bamigboye 2003
    1. Bamigboye AA, Morris J. Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD004353] - DOI - PMC - PubMed
Barnes 1980
    1. Barnes AB, Colton T, Gundersen J, Noller KL, Tilley BC, Strama T, et al. Fertility and outcome of pregnancy in women exposed in utero to diethylstilbestrol. New England Journal of Medicine 1980;302(11):609‐13. - PubMed
Bengtsson 1973
    1. Bengtsson LP. Hormonal effects on human myometrial activity. Vitamins and Hormones 1973;31:257‐303. - PubMed
Berger 1980
    1. Berger MJ, Goldstein DP. Impaired reproductive performance in DES‐exposed women. Obstetrics & Gynecology 1980;55(1):25‐7. - PubMed
Bibbo 1977
    1. Bibbo M, Gill WB, Azizi F, Blough R, Fang VS, Rosenfield RL, et al. Follow‐up study of male and female offspring of DES‐exposed mothers. Obstetrics & Gynecology 197;49(1):1‐8. - PubMed
Bibbo 1978
    1. Bibbo M, Haenszel WM, Wied GL, Hubby M, Herbst AL. A twenty‐five‐year follow‐up study of women exposed to diethylstilbestrol during pregnancy. New England Journal of Medicine 1978;298(14):763‐6. - PubMed
Burgoyne 1991
    1. Burgoyne PS, Holland K, Stephens R. Incidence of numerical chromosome anomalies in human pregnancy estimation from induced and spontaneous abortion data. Human Reproduction 1991;6(4):555‐65. - PubMed
Carrington 2005
    1. Carrington B, Sacks G, Regan L. Recurrent miscarriage: pathophysiology and outcome. Current Opinion in Obstetrics and Gynecology 2005;17:591‐7. - PubMed
Cunningham 2010
    1. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. Chapter 9. Abortion. Williams Obstetrics. 23rd Edition. New York: McGraw‐Hill Companies, 2010.
Davar 2007
    1. Davar R, Eftekhar M, Tayebi N. Transfer of cryopreserved‐thawed embryos in a cycle using exogenous steroids with or without prior gonadotrophin‐releasing hormone agonist. Journal of Medical Sciences 2007;7(5):880‐3.
Daya 2009
    1. Daya S. Luteal support: progestogens for pregnancy protection. Maturitas. Supplementum 2009;65:S29‐S34. - PubMed
de Ziegler 1990
    1. Ziegler D, Frydman R. Different implantation rates after transfers of cryopreserved embryos originating from donated oocytes or from regular in vitro fertilization. Fertility and Sterility 1990;54(4):682‐8. - PubMed
Devroey 1998
    1. Devroey P, Pados G. Preparation of endometrium for egg donation. Human Reproduction 1998;4(6):856‐61. - PubMed
Duan 2010
    1. Duan L, Yan D, Zeng W, Yang X, Wei Q. Effect of progesterone treatment due to threatened abortion in early pregnancy for obstetric and perinatal outcomes. Early Human Development 2010;86:41‐3. - PubMed
Everett 1997
    1. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997;315(7099):32‐4. - PMC - PubMed
FDA 1971
    1. FDA Drug Bulletin. Diethylstilboestrol Contraindicated in Pregnancy. US Dept of Health, Education and Welfare, 1971.
Garcia‐Enguidanos 2002
    1. Garcia‐Enguidanos A, Calle ME, Valero J, Luna S, Dominguez‐Rojas V. Risk factors in miscarriage: a review. European Journal of Obstetrics & Gynecology and Reproductive Biology 2002;102:111‐9. - PubMed
Gates 2009
    1. Gates S. Cochrane Pregnancy and Childbirth Group Methodological Guidelines. http://pregnancy.cochrane.org/sites/pregnancy.cochrane.org/files/uploads... (accessed 2010).
Genuth 2006
    1. Genuth SM. Chapter 52: Female reproduction. In: Levy MN, Stanton BA, Koeppen BM editor(s). Berne & Levy Principles of Physiology. 4th Edition. Philadelphia: Elsevier Mosby, 2006:725‐46.
Goddijin 2000
    1. Goddijn M, Leschot NJ. Genetic aspects of miscarriage. Clinical Obstetrics and Gynecology 2000;14(5):855‐65. - PubMed
Goldberg 1999
    1. Goldberg JM, Falcone T. Effect of diethylstilbestrol on reproductive function. Fertility and Sterility 1999;72(1):1‐7. - PubMed
Haas 2008
    1. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD003511.pub2] - DOI - PubMed
Habayeb 2004
    1. Habayeb OMH, Konje JC. The one‐stop recurrent miscarriage clinic: an evaluation of its effectiveness and outcome. Human Reproduction 2004;19(12):2952‐8. - PubMed
Hemminki 1999
    1. Hemminki E, Gissler M, Merilainen J. Reproductive effects of in utero exposure to estrogen and progestin drugs. Fertility and Sterility 1999;71(6):1092‐8. - PubMed
Herbst 1971
    1. Herbst AL, Ulfelder H, Poskanzer DC. Association of maternal stilbestrol therapy with tumor appearance in young women. New England Journal of Medicine 1971;284(16):878‐81. - PubMed
Herbst 1981
    1. Herbst AL. Clear cell adenocarcinoma and the current status of DES‐exposed females. Cancer 1981;48(2):484‐8. - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Janssen 1996
    1. Janssen HJEM, Cuisinier MCJ, Hoogduin KAL, Graauw KPHM. Controlled perspective study on the mental health of women following pregnancy loss. American Journal of Psychiatry 1996;153(2):226‐30. - PubMed
Johnson 1979
    1. Johnson LD, Driscoll SG, Hertig AT, Cole PT, Nickerson RJ. Vaginal adenosis in stillborns and neonates exposed to diethylstilbestrol and steroidal estrogens and progestins. Obstetrical and Gynecological Survey 1979;34(11):845‐6. - PubMed
Kullander 1976
    1. Kullander S, Kallen B. A prospective study of drugs and pregnancy. 3. Hormones. Acta Obstetricia et Gynecologica Scandinavica 1976;55(3):221‐4. - PubMed
Lee 1996
    1. Lee C, Slade P. Miscarriage as a traumatic event: a review of the literature and new implications for intervention. Journal of Psychosomatic Research 1996;40(3):235‐44. - PubMed
Lelaidier 1992
    1. Lelaidier C, Ziegler D, Gaetano J, Hazout A, Fernandez H, Frydman R. Controlled preparation of the endometrium with exogenous oestradiol and progesterone: a novel regimen not using a gonadotrophin‐releasing hormone agonist. Human Reproduction 1992;7(10):1353‐6. - PubMed
Li 2002
    1. Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: aetiology, management and prognosis. Human Reproduction Update 2002;8(5):463‐81. - PubMed
Liu 1991
    1. Liu H‐C, Rosenwaks Z. Early pregnancy wastage in IVF (in vitro fertilization) patients. Journal of in Vitro Fertilization and Embryo Transfer 1991;8(2):65‐72. - PubMed
Mills 1988
    1. Mills JL, Simpson JL, Driscoll SG, Jovanovic‐Peterson L, Allen MV, Aarons JH, et al. Incidence of spontaneous abortion among normal women and insulin‐dependent diabetic women whose pregnancies were identified within 21 days of conception. New England Journal of Medicine 1988;319(25):1617‐23. - PubMed
Muasher 1991
    1. Muasher SJ, Kruithoff C, Simonetti S, Oehninger S, Acosta AA, Jones GS. Controlled preparation of the endometrium with exogenous steroids for the transfer of frozen‐thawed pre‐embryos in patients with anovulatory or irregular cycles. Human Reproduction 1991;6(3):443‐5. - PubMed
Navot 1986
    1. Navot DN, Laufer NL, Kopolovic J, Rabinowitz R, Birkenfeld A, Lewin A, et al. Artificially induced endometrial cycles and establishment of pregnancies in the absence of ovaries. New England Journal of Medicine 1986;314:806‐11. - PubMed
Nesbitt 1965
    1. Nesbitt RE Jr, Aubry RH, Goldberg EM, Jacobs RD. Correlated hormone excretion patterns and cytohormone variations in normal and complicated pregnancies: Influence of administration of ovarian steroids or placebo in relation to outcome of pregnancy. American Journal of Obstetrics and Gynecology 1965;93(5):702‐19. - PubMed
Oats 2010
    1. Oats J, Abraham S. Chapter 11 Miscarriage and abortion. In: Oats J, Abraham S editor(s). Llewellyn‐Jones Fundamentals of Obstetrics and Gynaecology. 9th Edition. Elsevier Limited, 2010:99‐106.
Palmer 2005
    1. Palmer JR, Wise LA, Robboy SJ, Titus‐Ernstoff L, Noller KL, Herbst AL, et al. Hypospadias in sons of women exposed to diethylstilbestrol in utero. Epidemiology 2005;16(4):583‐6. - PubMed
Perez 2005
    1. Perez KM, Titus‐Ernstoff L, Hatch EE, Troisi R, Wactawski‐Wende J, Palmer JR, et al. Reproductive outcomes in men with prenatal exposure to diethylstilbestrol. Fertility and Sterility 2005;84(6):1649‐56. - PubMed
Porter 2008
    1. Porter TF, Branch DW, Scott JR. Early pregnancy loss. In: Gibbs RS, Karlan BY, Haney AF, Nygaard IE editor(s). Danforth's Obstetrics & Gynecology. 9th Edition. Philadelphia: Lippincott Williams & Wilkins, 2008:61‐71.
Potdar 2005
    1. Potdar N, Konje JC. The endocrinological basis of recurrent miscarriages. Current Opinion in Obstetrics and Gynecology 2005;17:424‐8. - PubMed
Queenan 1994
    1. Queenan JT, Weeck LL, Seltman HJ, Muasher SJ. Transfer of cryopreserved‐thawed pre‐embryos in a natural cycle or a programmed cycle with exogenous hormonal replacement yields similar pregnancy results. Fertility and Sterility 1994;62(3):545‐50. - PubMed
Queenan 1997
    1. Queenan JT, Ramey JW, Seltman HJ, Eure L, Veeck LL, Muasher SJ. Transfer of cryopreserved‐thawed pre‐embryos in a cycle using exogenous steroids without prior gonadotrophin‐releasing hormone agonist suppression yields favourable pregnancy results. Human Reproduction 1997;12(6):1176‐80. - PubMed
Rao 1998
    1. Rao CV. Novel concepts in neuroendocrine regulation of reproductive tract functions. In: Bazer FW editor(s). Endocrinology of Pregnancy. Totowa: Humana Press Inc, 1998:125‐44.
RCOG 2003
    1. Regan L, Backos MJ, Rai R. The investigation and treatment of couples with recurrent miscarriage. Royal College of Obstetricians and Gynaecologists Green‐top Guideline No. 17. London: RCOG, 2003.
RCOG 2006
    1. Hinshaw K, Fayyad A, Munjuluri P. The management of early pregnancy loss. Royal College of Obstetricians and Gynaecologists Green‐top Guideline No. 25. London: RCOG, 2006.
Regan 1989
    1. Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989;299:541‐5. - PMC - PubMed
RevMan 2012 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Schindler 2005
    1. Schindler AE. Endocrinology of pregnancy: consequences for the diagnosis and treatment of pregnancy disorders. Journal of Steroid Biochemistry and Molecular Biology 2005;97:386‐8. - PubMed
Schmidt 1989
    1. Schmidt CL, Taney FH, Ziegler D, Kuhar MJ, Gagliardi CL, Colon JM, et al. Transfer of cryopreserved‐thawed embryos: the natural cycle versus controlled preparation of the endometrium with gonadotropin‐releasing hormone agonist and exogenous estradiol and progesterone (GEEP). Fertility and Sterility 1989;52(4):609‐16. - PubMed
Schorge 2008
    1. Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG. Chapter 15. Reproductive endocrinology. In: Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG editor(s). Williams Gynecology. New York: McGraw‐Hill Companies, 2008.
Silver 1999
    1. Silver RI, Rodriguez R, Chang TSK, Gearhart JP. In vitro fertilization is associated with an increased risk of hypospadias. Journal of Urology 1999;161:1954‐7. - PubMed
Simpson 2007
    1. Simpson JL. Causes of fetal wastage. Clinical Obstetrics and Gynecology 2007;50(1):10‐30. - PubMed
Smith 1948
    1. Smith OW. Diethylstilboestrol in the prevention and treatment of complications of pregnancy. American Journal of Obstetrics and Gynecology 1948;56:821‐34. - PubMed
Speroff 2005
    1. Speroff L, Fritz MA. Steroid hormones in pregnancy. In: Speroff L, Fritz MA editor(s). Clinical Gynecologic Endocrinology and Infertility. 7th Edition. Philadelphia: Lippincott Williams & Wilkins, 2005:259‐72.
Stirrat 1990
    1. Stirrat GM. Recurrent miscarriage I: definition and epidemiology. Lancet 1990;336:673‐5. - PubMed
Sullivan 1986
    1. Sullivan FM. Problems in the long‐term assessment of risks from drugs used in pregnancy maintenance. Human Reproduction 1986;1(7):459‐61. - PubMed
Thierstein 1959
    1. Thierstein ST, Rodler DEH. Norlutin and stilbestrol compared to progesterone and stilbestrol in treating threatened and repeated abortion. Nebraska State Medical Journal 1959;44:433‐41. - PubMed
Toth 2010
    1. Toth B, Jeschk U, Rogenhofer N, Scholz C, Würfel W, Thaler CJ, et al. Recurrent miscarriage: current concepts in diagnosis and treatment. Journal of Reproductive Immunology 2010;85:25‐32. - PubMed
Tulppala 1993
    1. Tulppala M, Palosuo T, Ramsay T, Miettinen A, Salonen R, Ylikorkala O. A prospective study of 63 couples with a history of recurrent spontaneous abortion: contributing factors and outcome of subsequent pregnancies. Human Reproduction 1993;8(5):764‐70. - PubMed
Wahabi 2011
    1. Wahabi HA, Abed Althagafi NF, Elawad M, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD005943.pub3] - DOI - PubMed
Walch 2008
    1. Walch KT, Huber JC. Progesterone for recurrent miscarriage: truth and deceptions. Best Practice and Research in Clinical Obstetrics and Gynaecology 2008;22(2):375‐89. - PubMed
Warburton 1964
    1. Warburton D, Fraser FC. Spontaneous abortion risks in man: data from reproductive histories collected in a medical genetics unit. Human Genetics 1964;15(1):1‐25. - PMC - PubMed
Wilcox 1988
    1. Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE, et al. Incidence of early loss of pregnancy. New England Journal of Medicine 1988;319(4):189‐94. - PubMed
Wilkins 1960
    1. Wilkins L. Masculinization of female fetus due to use of orally given progestins. JAMA 1960;172(10):1028‐32. - PubMed

References to other published versions of this review

Lim DCE 2011
    1. Lim DCE, Cheng LNC, Ho KKW, Wong FWS. Combined oestrogen and progesterone for preventing miscarriage. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009278] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources